37 citations,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
11 citations,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.
191 citations,
September 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
14 citations,
June 2017 in “Immunity” Special immune cells called Treg cells are important for maintaining and regenerating hair by activating a specific growth signal in hair stem cells.
102 citations,
January 2018 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Restoring hair bulb immune privilege is crucial for managing alopecia areata.
83 citations,
June 2018 in “Frontiers in immunology” Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.
49 citations,
October 2014 in “International Scholarly Research Notices” Eclipta alba has many health benefits and contains compounds with potential for drug development.
25 citations,
August 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
14 citations,
January 2017 in “Skin appendage disorders” Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.
9 citations,
May 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
1 citations,
January 2017 in “Springer eBooks” Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
37 citations,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
11 citations,
April 2015 in “EBioMedicine” JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
79 citations,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
40 citations,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
A teenager had both alopecia areata and vitiligo, which are rare to occur together.
138 citations,
August 2019 in “Stem Cells and Development” Periodontal ligament stem cells show promise for regrowing tissues but require more research for safe, effective use.
April 2023 in “Medizinische Genetik” New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.
November 2015 in “European Journal of Inflammation” Cicatricial alopecia, a permanent hair loss condition, is mainly caused by damage to specific hair follicle stem cells and abnormal immune responses, with gene regulator PPAR-y and lipid metabolism disorders playing significant roles.
11 citations,
September 2014 in “International Journal of Molecular Sciences” Mycophenolate helps reverse hair loss effects caused by IFN-γ by activating a key hair growth pathway.
9 citations,
May 2005 in “Expert Review of Clinical Immunology” Blocking interferon-gamma might help treat various autoimmune diseases.
36 citations,
August 2016 in “British journal of dermatology/British journal of dermatology, Supplement” A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.
1 citations,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
31 citations,
February 2014 in “Inflammation Research” Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.
157 citations,
February 2016 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
6 citations,
December 2017 in “Molecular Medicine Reports” Wnt5a may contribute to psoriasis by reducing skin cell growth, blocking skin cell maturation, and increasing inflammation.
159 citations,
July 2006 in “Endocrine Reviews” Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.
421 citations,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.